Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase : Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr1a/b Gene Disruption on Tissue Distribution in Mice

スポンサーリンク

概要

• 論文の詳細を見る
• 2002-12-16

著者

• Kojima Juniji

  興和株式会社東京研究所

• Kojima Junji

  Tokyo New Drug Research Laboratories Kowa Company Ltd.

• Kojima Junji

  Ntt Human Interface Laboratories

• Fujino Hideki

  Tokyo New Drug Research Laboratories Kowa Company Ltd.

• SHIMADA Syunsuke

  Tokyo New Drug Research Laboratories, Kowa Company Ltd.

• YAMADA Iwao

  Tokyo New Drug Research Laboratories I, Kowa Company Ltd.

• Yamada Iwao

  Tokyo New Drug Research Laboratories I Kowa Company Ltd.

• Shimada Syunsuke

  Tokyo New Drug Research Laboratories Kowa Company Ltd.

関連論文

• Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (4) : Interspecies Variation in Laboratory Animals and Humans
• Effect of Biliary Excretion on the Pharmacokinetics of Pitavastatin (NK-104) in Dogs
• Uptake Mechanism of Pitavastatin, a New Inhibitor of HMG-CoA Reductase, in Rat Hepatocytes
• Metabolic Fate of Pitavastatin, a New Inhibitor of HMG-CoA Reductase : Effect of cMOAT Deficiency on Hepatobiliary Excretion in Rats and of mdr1a/b Gene Disruption on Tissue Distribution in Mice
• Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reduetase (5) : In Vitro Metabolism and Plasma Protein Binding in Animals and Human
• Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
• Identification of Metabolites of NK-104,an HMG-CoA Reductase Inhibitor, in Rat, Rabbit and Dog Bile
• A Fast Projection Algorithm for Adaptive Filtering
• Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (2) : Absorption, Distribution, Metabolism, Excretion and Accumulation Following Repeated Oral Administration of ^C-NK-104 in Rats
• Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (1) : Absorption, Distribution, Metabolism and Excretion in Rats
• PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. I. STUDIES ON INTERSPECIES VARIATION IN LABORATORY ANIMALS
• PHARMACOKINETICS OF NIPRADILOL (K-351), A NEW ANTIHYPERTENSIVE AGENT. II. INFLUENCE OF THE ROUTE OF ADMINISTRATION ON BIOAVAILABILITY IN DOGS
• Studies on metabolic fate of pitavastatin (NK-104), a new inhibitor of HMG-CoA reductase-Does glucronidation mediate the lactonization of pitavastatin?
• Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay-inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase
• Studies on the Metabolic Fate of NK-104, a New Inhibitor of HMG-CoA Reductase (3) : Foeto-placental Transfer and Mammary Excretion after Oral Administration in Rats
• Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent, in human.

もっと見る 閉じる

スポンサーリンク